कंपनी का अवलोकन
Rezolute, Inc. operates as a late-stage rare disease company dedicated to enhancing clinical outcomes for individuals suffering from hypoglycemia caused by hyperinsulinism within the United States. The corporation functions within the broader Healthcare sector and specifically targets the Biotechnology industry, focusing on the development of specialized therapeutics for underserved patient populations. Currently, the company employs a workforce of 75 individuals and maintains a market capitalization of $340.68 million. This valuation, combined with a reported annual revenue status of N/A, indicates that the market values Rezolute primarily on its clinical pipeline assets rather than current cash-flow generation, which is typical for biotechnology firms in the late-stage development phase.
वित्तीय स्वास्थ्य
The company reports a net income of $-84,228,000 for the trailing twelve months, while revenue and EBITDA figures are listed as N/A and $-88,381,000 respectively. The significant gap between the reported net income and the EBITDA figure reveals a substantial cost structure burden, specifically driven by non-operating expenses or interest costs that reduce the bottom line below the operational earnings level. Free cash flow stands at $-46,168,876, which signifies that the company is burning cash to fund its research and development activities rather than generating liquidity from operations. Despite these negative cash flows, Rezolute holds a cash reserve of $132.94 million, which provides a buffer against current expenditures. The balance sheet shows minimal debt obligations of $1.28 million against a debt-to-equity ratio of 1.00, suggesting a leveraged but manageable capital structure given the high cash holdings. Operating margins, gross margins, and profit margins are all recorded at 0.0%, indicating that the company has not yet achieved profitability or is presenting unadjusted figures common in pre-commercialization biotech models. The current ratio is an exceptionally high 14.18, demonstrating robust short-term liquidity and the ability to cover immediate liabilities many times over. Return on Equity is negative at -74.0% and Return on Assets is -44.1%, metrics that reveal that management effectiveness is currently constrained by the capital-intensive nature of drug development rather than operational efficiency.
मूल्यांकन आकलन
The trailing P/E ratio is listed as N/A due to the lack of positive earnings, while the forward P/E is calculated at -5.20, reflecting the expectation of continued losses in the near term. The price-to-book ratio stands at 2.88, which indicates that the market is pricing the company at a significant premium over its net book value, valuing its intellectual property and clinical potential higher than its tangible assets. Alternative valuation metrics such as the price-to-sales ratio (N/A) and EV/EBITDA (-2.37) suggest that traditional multiple-based comparisons are not applicable due to the absence of sales and negative earnings. The stock has traded between a 52-week high of $11.46 and a 52-week low of $1.07, illustrating a wide trading range that reflects high volatility in small-cap biotechnology equities. The beta of 0.66 indicates that the stock's price volatility is lower than the broader market, suggesting it may be less sensitive to general market fluctuations despite its high growth risk profile.
Growth & Income
Revenue growth and earnings growth rates are both listed as N/A, meaning historical growth trajectories cannot be calculated from the available trailing twelve-month data. Since the company does not pay a dividend, the dividend yield is N/A and the payout ratio is 0.0%, indicating that all available earnings are retained to fund operations and research rather than being distributed to shareholders. The negative net income and negative free cash flow imply that earnings are not yet growing from a profitable base, but rather that the company is in a capital-depletion phase typical of late-stage biotechnology. Consequently, the overall growth and income profile for Rezolute, Inc. is characterized by significant cash consumption to support the Phase 3 clinical trial for its lead asset, ersodetug, with no current dividend income available to investors.